Paperbase

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action

Calland, Noemie Sahuc, Marie-Emmanuelle Belouzard, Sandrine Pene, Veronique Bonnafous, Pierre Mesalam, Ahmed Atef Deloison, Gaspard Descamps, Veronique Sahpaz, Sevser Wychowski, Czeslaw Lambert, Olivier Brodin, Priscille Duverlie, Gilles Meuleman, Philip Rosenberg, Arielle R. Dubuisson, Jean Rouille, Yves Seron, Karin

Journal of virology, 2015-10

https://doi.org/10.1128/jvi.01473-15

Sandrine Belouzard

Belouzard Sandrine

ORCID: 0000-0002-9972-4054

Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus 10.1128/JVI.00404-16

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin 10.1016/j.antiviral.2016.07.011

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans 10.1128/JVI.03647-14

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/JVI.00192-15

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/JVI.01473-15

Regulation of core expression during the hepatitis C virus life cycle 10.1099/vir.0.070433-0

Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents 10.1002/hep.27196

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells 10.1371/journal.pone.0074491

Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus 10.1371/journal.pone.0070809

The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus 10.1002/hep.26273

Utilization of human DC-SIGN and L-SIGN for entry and infection of host cells by the New World arenavirus, Junin virus 10.1016/j.bbrc.2013.10.106

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein 10.3390/v4061011

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle 10.1002/hep.25501

Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway 10.1074/jbc.M111.224857

Griffithsin Has Antiviral Activity against Hepatitis C Virus 10.1128/AAC.00633-11

Hepatitis C virus entry into the hepatocyte 10.2478/s11535-011-0076-y

Elastase-mediated Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein at Discrete Sites within the S2 Domain 10.1074/jbc.M110.103275

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites 10.1073/pnas.0809524106

Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide 10.1128/JVI.00079-09

SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion 10.1016/j.virol.2009.07.038

Molecular architecture of the bipartite fusion loops of vesicular stomatitis virus glycoprotein G, a class III viral fusion protein 10.1074/jbc.M708955200

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity 10.1073/pnas.0706671104

Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway. 10.1074/jbc.m400508200

Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. 10.1074/jbc.m406315200

Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis. 10.1128/jvi.79.16.10826-10829.2005

Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis. 10.1038/sj.emboj.7600989

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. 10.1128/jvi.80.6.2832-2841.2006

Entry and release of hepatitis C virus in polarized human hepatocytes. 10.1128/JVI.00478-17

Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes 10.1053/j.gastro.2018.03.020

The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal 10.1074/jbc.RA119.008964

Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers 10.1101/2020.05.12.20098236

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress. 10.3390/cells10082047

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. 10.1128/aac.00097-21

Olivier Lambert

Lambert Olivier

ORCID: 0000-0002-5651-8082

Trimeric structure of OprN and OprM efflux proteins from Pseudomonas aeruginosa, by 2D electron crystallography 10.1016/j.jsb.2005.01.001

High-yield preparation of polystyrene/silica clusters of controlled morphology 10.1039/c2py20058a

Polyphenols inhibit hepatitis C virus entry by a new mechanism of action 10.1128/JVI.01473-15

Minimal nanodisc without exogenous lipids for stabilizing membrane proteins in detergent-free buffer 10.1016/j.bbamem.2019.01.013

Modeling leakage kinetics from multilamellar vesicles for membrane permeability determination: Application to glucose 10.1529/biophysj.106.088401

Hepatitis B subvirus particles display both a fluid bilayer membrane and a strong resistance to freeze drying: A study by solid-state NMR, light scattering, and cryo-electron microscopy/tomography 10.1096/fj.13-232843

An approach to the intramolecular localization of the thiol ester bonds in the internal cavity of human α2-macroglobulin based on correspondence analysis 10.1006/jsbi.1994.1016

Multilamellar liposomes entrapping aminosilane-modified maghemite nanoparticles: “Magnetonions” 10.1039/c0cp00231c

Two-dimensional crystallization on lipid layer: A successful approach for membrane proteins 10.1006/jsbi.1999.4155

The encapsulation of DNA molecules within biomimetic lipid nanocapsules 10.1016/j.biomaterials.2009.03.009

Three-dimensional reconstruction of Limulus polyphemus hemocyanin from cryoelectron microscopy 10.1006/jmbi.1996.0840

Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference 10.1073/pnas.0707431104

Metallic oxide nanoparticle translocation across the human bronchial epithelial barrier 10.1039/c4nr07079h

Protein-mediated DNA transfer into liposomes 10.1046/j.1365-2958.1998.01107.x

Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. 10.1093/nar/gnh153

Membrane protein selectively oriented on solid support and reconstituted into a lipid membrane 10.1021/la062227z

Self-assembling complexes between binary mixtures of lipids with different linkers and nucleic acids promote universal mRNA, DNA and siRNA delivery 10.1016/j.jconrel.2017.01.041

Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes 10.1002/jgm.1212

Synthesis and self-assembly of branched glycopolypeptides: Effect of topology and conformation 10.1039/c3fd00082f

Regioselective Coating of Tetrapod-like Clusters with Silica 10.1080/15421406.2014.967651

Organization of reconstituted lipoprotein MexA onto supported lipid membrane 10.1007/s00249-007-0208-5

Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis c virus glycoproteins 10.1074/jbc.M110.131664

Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads 10.1099/vir.0.021071-0

The homeodomain derived peptide penetratin induces curvature of fluid membrane domains 10.1371/journal.pone.0001938

Three-dimensional reconstruction from a frozen-hydrated specimen of the chiton Lepidochiton sp. hemocyanin 10.1006/jmbi.1994.1757

N-Heterocyclic Carbene-Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy 10.1021/acs.bioconjchem.6b00320

The motor protein Myosin-X transports VE-cadherin along filopodia to allow the formation of early endothelial cell-cell contacts 10.1128/MCB.01226-09

Detergent removal by non-polar polystyrene beads: Applications to membrane protein reconstitution and two-dimensional crystallization 10.1007/s002490050138

Caveolae-mediated effects of TNF-α on human skeletal muscle cells 10.1016/j.yexcr.2018.07.027

Quaternary structure of Octopus vulgaris hemocyanin: Three-dimensional reconstruction from frozen-hydrated specimens andintramolecular location of functional units Ove and Ovb 10.1006/jmbi.1994.1269

Cryo-electron tomography of nanoparticle transmigration into liposome 10.1016/j.jsb.2009.07.006

Novel Organization and Properties of Annexin 2-Membrane Complexes 10.1074/jbc.M313657200

Paromomycin and neomycin B derived cationic lipids: Synthesis and transfection studies 10.1016/j.jconrel.2011.12.019

DNA delivery by phage as a strategy for encapsulating toroidal condensates of arbitrary size into liposomes 10.1073/pnas.130187297

Use of octyl β-thioglucopyranoside in two-dimensional crystallization of membrane proteins 10.1006/jsbi.2001.4344

Three-Dimensional Reconstruction of the Hemocyanin of the Protobranch Bivalve Mollusk Nucula hanleyi from Frozen-Hydrated Specimens 10.1006/abbi.1995.1287

Design of Ionizable Lipids to Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA 10.1021/acs.jmedchem.5b01679

Structure of reconstituted bacterial membrane efflux pump by cryo-electron tomography 10.1016/j.bbamem.2010.06.019

Oxidative stress induces Caveolin 1 degradation and impairs Caveolae functions in skeletal muscle cells 10.1371/journal.pone.0122654

Synthesis of stable, gold-particle-containing onion-type multilamellar vesicles. Influence of particle size on the onions' internal structure 10.1088/0957-4484/17/5/005

Two-dimensional structures of the shiga toxin B-subunit and of a chimera bound to the glycolipid receptor Gb3 10.1016/S1047-8477(02)00504-X

Structure determination of membrane protein by both cryo-electron tomography and single particle analysis. 10.1007/978-1-60761-762-4_11

A chemical synthetic route towards "Colloidal molecules" 10.1002/anie.200802562

Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope 10.1371/journal.ppat.1005476

Nitroxide-Mediated Polymerization-Induced Self-Assembly of Block Copolymers at the Surface of Silica Particles: Toward New Hybrid Morphologies 10.1021/acs.macromol.7b00033

Treatment of influenza virus with Beta-propiolactone alters viral membrane fusion 10.1016/j.bbamem.2013.09.021

Probing the in vitro mechanism of action of cationic lipid/DNA lipoplexes at a nanometric scale 10.1093/nar/gkq921

Amphiphilic block copolymers enhance the cellular uptake of DNA molecules through a facilitated plasma membrane transport 10.1093/nar/gkq922

Use of detergents in two-dimensional crystallization of membrane proteins 10.1016/S0005-2736(00)00307-2

Involvement of caveolin-1 and CD36 in native LDL endocytosis by endothelial cells 10.1016/j.bbagen.2019.01.005

FhuA-mediated phage genome transfer into liposomes: A cryo-electron tomography study 10.1016/S0960-9822(01)00349-9

Electrokinetic assembly of one-dimensional nanoparticle chains with cucurbit[7]uril controlled subnanometer junctions 10.1021/nl403224q

Asymmetrical membranes and surface tension 10.1016/S0006-3495(02)73915-5

An 8-Å projected structure of FhuA, a 'ligand-gated' channel of the Escherichia coli outer membrane 10.1006/jsbi.1999.4115

Magnetic multilamellar liposomes produced by in situ synthesis of iron oxide nanoparticles: "Magnetonions" 10.1021/jp901105c

Planar submicronic silica-polystyrene particles obtained by substrate-directed shaping 10.1039/b901901d

Liposome-based Formulation for Intracellular Delivery of Functional Proteins 10.1038/mtna.2015.17

Interaction of Aβ1-42 Amyloids with Lipids Promotes "Off-Pathway" Oligomerization and Membrane Damage 10.1021/bm501837w

A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles 10.1089/104303402760293592

FhuA, an Escherichia coli outer membrane protein with a dual function of transporter and channel which mediates the transport of phage DNA 10.1016/S0300-9084(00)80004-8

Piceatannol and other wine stilbenes: A pool of inhibitors against α-synuclein aggregation and cytotoxicity 10.3390/nu8060367

Antibiotic export by MexB multidrug efflux transporter is allosterically controlled by a MexA-OprM chaperone-like complex 10.1038/s41467-020-18770-5

Relationships between the physicochemical properties of an amphiphilic triblock copolymers/DNA complexes and their intramuscular transfection efficiency 10.1093/nar/gkl860

Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses 10.1016/j.vaccine.2019.05.012

Structural organization of molluscan hemocyanins 10.1016/0248-4900(96)89453-6

A yeast toxic mutant of HET-s amyloid disrupts membrane integrity 10.1016/j.bbamem.2012.04.013

Tripartite assembly of RND multidrug efflux pumps 10.1038/ncomms10731

Phage DNA transfer into liposomes 10.1016/S0076-6879(03)73029-8

A new 'gel-like' phase in dodecyl maltoside-lipid mixtures: Implications in solubilization and reconstitution studies 10.1016/S0006-3495(98)74015-9

Synthesis of unsymmetrical saturated or diacetylenic cationic bolaamphiphiles 10.1016/j.tetlet.2008.10.073

Spheres growing on a sphere: A model to predict the morphology yields of colloidal molecules obtained through a heterogeneous nucleation route 10.1021/la301857h

Physicochemical parameters of non-viral vectors that govern transfection efficiency 10.2174/156652308786070961

Further Approaches to the Quaternary Structure of Octopus Hemocyanin: A Model Based on Immunoelectron Microscopy and Image Processing 10.1006/abbi.1993.1388

The basic framework of VE-cadherin junctions revealed by cryo-EM 10.1016/j.jmb.2004.12.053

Shaping quaternary assemblies of water-soluble non-peptide helical foldamers by sequence manipulation 10.1038/nchem.2353

Quaternary ammonium groups exposed at the surface of silica nanoparticles suitable for DNA complexation in the presence of cationic lipids 10.1021/acs.jpcb.5b01834

Different molecular arrangements of the tetrameric annexin 2 modulate the size and dynamics of membrane aggregation 10.1016/j.bbamem.2010.05.001

Three-dimensional reconstruction of the chlorocruorin of the polychaete annelid Eudistylia vancouverii 10.1006/jmbi.1996.0012

How the stereochemistry of a central cyclopentyl ring influences the self-assembling properties of archaeal lipid analogues: Synthesis and cryoTEM observations 10.1021/jo201827h

The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy 10.1021/nl048153y

Lipid domain separation, bilayer thickening and pearling induced by the cell penetrating peptide penetratin 10.1016/j.bbamem.2009.12.024

Visualization of adherent cell monolayers by cryo-electron microscopy: A snapshot of endothelial adherens junctions 10.1016/j.jsb.2015.10.009

Internalization and fate of silica nanoparticles in C2C12 skeletal muscle cells: Evidence of a beneficial effect on myoblast fusion 10.2147/IJN.S74158

Cancer-specific transgene expression mediated by systemic injection of nanoparticles 10.1158/0008-5472.CAN-08-2657

Three-dimensional reconstruction of the αD and βC-hemocyanins of Helix pomatia from frozen-hydrated specimens 10.1016/s0022-2836(95)80061-1

Three-dimensional reconstruction of Macrobdella decora (leech) hemoglobin by cryoelectron microscopy 10.1016/S0006-3495(96)79762-X

Colloidal alchemy: Conversion of polystyrene nanoclusters into gold 10.1002/cnma.201600315

Important role of phosphoramido linkage in imidazole-based dioleyl helper lipids for liposome stability and primary cell transfection 10.1002/jgm.2869

Structure of artificial and natural VE-cadherin-based adherens junctions 10.1042/BST0360189

Three-dimensional reconstruction of Sepia officinalis hemocyanin from frozen-hydrated specimens 10.1006/abbi.1995.1126

Sterically stabilized BGTC-based lipoplexes: Structural features and gene transfection into the mouse airways in vivo 10.1002/jgm.211

Gold fractal structures spontaneously grown in sheared lamellar phase 10.1039/b605988k

Multipod-like silica/polystyrene clusters 10.1039/c5nr07613g

Single lipoaminoglycoside promotes efficient intracellular antibody delivery: A comprehensive insight into the mechanism of action 10.1016/j.nano.2017.09.005

Annexin-A6 presents two modes of association with phospholipid membranes. A combined QCM-D, AFM and cryo-TEM study 10.1016/j.jsb.2009.03.007

Two-dimensional crystallization of proteins on lipid monolayers at the air - Water interface and transfer to an electron microscopy grid 10.1016/S0022-0248(98)00834-3

Charge detection mass spectrometry for the characterization of mass and surface area of composite nanoparticles 10.1021/jp510081v

Production of magnetic multilamellar liposomes as highly T2-efficient MRI contrast agents 10.1016/j.nano.2010.10.011

Structural analysis of junctions formed between lipid membranes and several annexins by cryo-electron microscopy 10.1006/jmbi.1997.1183

New insights into the nucleation and growth of PS nodules on silica nanoparticles by 3D cryo-electron tomography 10.1039/b710137f

Coiled-coil oligomerization controls localization of the plasma membrane REMORINs 10.1016/j.jsb.2018.02.003

Structural characterization of the EmrAB-TolC efflux complex from E. coli 10.1016/j.bbamem.2020.183488

A Cell-Penetrating Foldamer with a Bioreducible Linkage for Intracellular Delivery of DNA 10.1002/anie.201504884

Gene transfer by histidylated lipopolyplexes: A dehydration method allowing preservation of their physicochemical parameters and transfection efficiency 10.1016/j.ijpharm.2011.04.009

Reconstitution of membrane proteins into nanodiscs for single-particle electron microscopy 10.1007/978-1-4939-7151-0_17

Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation 10.1002/advs.201900288

Structure of membrane-bound annexin A5 trimers: A hybrid Cryo-EM - X-ray crystallography study 10.1006/jmbi.2000.4183

Yves Rouillé

Rouillé Yves

ORCID: 0000-0003-0788-9271

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon 10.1016/s0014-5793(97)00892-2

Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1 10.1074/jbc.272.52.32810

Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: A potential mechanism for its inactivation 10.1073/pnas.93.10.4919

DISTINCT HYDRO-OSMOTIC RECEPTORS FOR THE NEUROHYPOPHYSEAL PEPTIDES VASOTOCIN AND HYDRINS IN THE FROG RANA-ESCULENTA 10.1016/0143-4179(95)90039-x

HYPERPROINSULINAEMIA IN OBESE FAT/FAT MICE ASSOCIATED WITH A CARBOXYPEPTIDASE-E MUTATION WHICH REDUCES ENZYME-ACTIVITY 10.1038/ng0695-135

PROTEOLYTIC PROCESSING MECHANISMS IN THE BIOSYNTHESIS OF NEUROENDOCRINE PEPTIDES - THE SUBTILISIN-LIKE PROPROTEIN CONVERTASES 10.1006/frne.1995.1012

ACTION OF NEUROHYPOPHYSEAL GRANULE LYS-ARG ENDOPEPTIDASE ON SYNTHETIC POLYPEPTIDES COMPRISING THE PROCESSING SEQUENCE OF PROVASOPRESSIN-NEUROPHYSIN 10.1007/bf01200246

PROGLUCAGON IS PROCESSED TO GLUCAGON BY PROHORMONE CONVERTASE PC2 IN ALPHA-TC1-6 CELLS 10.1073/pnas.91.8.3242

SPECIAL EVOLUTION OF NEUROHYPOPHYSEAL HORMONES IN CARTILAGINOUS FISHES - ASVATOCIN AND PHASVATOCIN, 2 OXYTOCIN-LIKE PEPTIDES ISOLATED FROM THE SPOTTED DOGFISH (SCYLIORHINUS-CANICULUS) 10.1073/pnas.91.23.11266

A NEUROSECRETORY GRANULE LYS-ARG CA2+-DEPENDENT ENDOPEPTIDASE PUTATIVELY INVOLVED IN PROOXYTOCIN AND PROVASOPRESSIN PROCESSING 10.1016/0143-4179(92)90050-7

EVIDENCE FOR DISTINCT DIBASIC PROCESSING ENDOPEPTIDASES WITH LYS-ARG AND ARG-ARG SPECIFICITIES IN NEUROHYPOPHYSEAL SECRETORY GRANULES 10.1016/0006-291x(92)91618-z

PROCESSING ENDOPEPTIDASE DEFICIENCY IN NEUROHYPOPHYSEAL SECRETORY GRANULES OF THE DIABETES-INSIPIDUS (BRATTLEBORO) RAT 10.1007/bf01122032

HETEROLOGUE CONVERSION OF AMPHIBIAN HYDRIN-2 INTO VASOTOCIN THROUGH BOVINE GRANULE ALPHA-AMIDATING ENZYME 10.1111/j.1365-2826.1991.tb00233.x

NEUROHYPOPHYSEAL HORMONES AS MOLECULAR EVOLUTIONARY TRACERS - INVESTIGATIONS ON THE STURGEONS ACIPENSER-STELLATUS AND ACIPENSER-GULDENSTADTI 10.1016/0305-0491(91)90280-q

EVOLUTIONARY SPECIFICITY OF HYDRINS, NEW HYDROOSMOTIC NEUROPEPTIDES - OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY) IN THE TOAD BUFO-MARINUS BUT NOT IN THE VIPER VIPERA-ASPIS 10.1016/0014-5793(90)80783-f

IDENTIFICATION OF 2 TYPES OF NEUROPHYSINS IN XENOPUS-LAEVIS NEUROINTERMEDIATE PITUITARY HOMOLOGOUS TO MAMMALIAN MSEL-NEUROPHYSIN AND VLDV-NEUROPHYSIN 10.1016/0143-4179(90)90142-l

OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY), A NEW HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDE, IN SECRETORY GRANULES ISOLATED FROM THE FROG (RANA-ESCULENTA) NEUROINTERMEDIATE PITUITARY 10.1159/000125343

HYDRINS, HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDES - OSMOREGULATORY ADAPTATION IN AMPHIBIANS THROUGH VASOTOCIN PRECURSOR PROCESSING 10.1073/pnas.86.14.5272

ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOTOCIN, MESOTOCIN, MSEL-NEUROPHYSINS AND VLDV-NEUROPHYSINS FROM GOOSE NEUROHYPOPHYSIS 10.1016/0143-4179(89)90090-5

PARTICULAR PROCESSING OF PRO-OPIOMELANOCORTIN IN XENOPUS-LAEVIS INTERMEDIATE PITUITARY - SEQUENCING OF ALPHA-MELANOCYTE-STIMULATING, AND BETA-MELANOCYTE-STIMULATING HORMONES 10.1016/0014-5793(89)80224-8

DUAL DUPLICATION OF NEUROHYPOPHYSEAL HORMONES IN AN AUSTRALIAN MARSUPIAL - MESOTOCIN, OXYTOCIN, LYSINE VASOPRESSIN AND ARGININE VASOPRESSIN IN A SINGLE GLAND OF THE NORTHERN BANDICOOT (ISOODON-MACROURUS) 10.1016/0006-291x(88)90691-2

ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOPRESSIN AND MSEL-NEUROPHYSIN FROM GUINEA-PIG NEUROINTERMEDIATE PITUITARY 10.1016/0143-4179(88)90025-x

NEUROHYPOPHYSEAL HORMONES OF THE 1-MONTH-OLD BOVINE FETUS - ABSENCE OF VASOTOCIN DURING MAMMAL DEVELOPMENT 10.1016/0014-5793(88)80113-3

THE DISTRIBUTION OF LYSINE VASOPRESSIN (LYSIPRESSIN) IN PLACENTAL MAMMALS - A REINVESTIGATION OF THE HIPPOPOTAMIDAE (HIPPOPOTAMUS-AMPHIBIUS) AND TAYASSUIDAE (TAYASSU-ANGULATUS) FAMILIES 10.1016/0016-6480(88)90277-8

EVOLUTION OF MARSUPIALS TRACED BY THEIR NEUROHYPOPHYSEAL HORMONES - MICROIDENTIFICATION OF MESOTOCIN AND ARGININE VASOPRESSIN IN 2 AUSTRALIAN FAMILIES, DASYURIDAE AND PHASCOLARCTIDAE 10.1016/0016-6480(87)90195-x

GUINEA-PIG NEUROHYPOPHYSEAL HORMONES - PECULIAR PROCESSING OF THE 3-DOMAIN VASOPRESSIN PRECURSOR 10.1016/0014-5793(87)81294-2

Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal 10.1210/me.2015-1211

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus 10.1128/jvi.00404-16

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope 10.1371/journal.ppat.1005476

Recent advances in human viruses imaging studies 10.1002/jobm.201500575

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/jvi.00192-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Regulation of core expression during the hepatitis C virus life cycle 10.1099/vir.0.070433-0

FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver 10.1186/1478-811x-12-4

Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis 10.5812/hepatmon.17812

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors 10.1016/j.bmcl.2014.07.051

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells 10.1371/journal.pone.0074491

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? 10.3390/v4102197

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle 10.1002/hep.25501

Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway 10.1074/jbc.M111.224857

HCV replication and assembly: a play in one act 10.2217/fvl.11.69

Hepatitis C Virus Assembly Imaging 10.3390/v3112238

Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies 10.1016/j.yexcr.2011.08.018

NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly 10.1371/journal.ppat.1001278

Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein 10.1099/vir.0.015339-0

Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity 10.1128/jvi.01393-10

Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication 10.1128/jvi.01190-09

LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice 10.1172/jci34997

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins 10.1099/vir.0.82872-0

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity 10.1073/pnas.0706671104

Hepatitis C virus entry depends on clathrin-mediated endocytosis 10.1128/jvi.00024-06

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus 10.1128/jvi.80.6.2832-2841.2006

Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis 10.1038/sj.emboj.7600989

Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis 10.1128/jvi.79.16.10826-10829.2005

Interactions between virus proteins and host cell membranes during the viral life cycle 10.1016/s0074-7696(05)45006-8

Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon 10.1210/en.2004-1118

Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway 10.1074/jbc.M400508200

The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals 10.1128/jvi.78.22.12591-12602.2004

Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells 10.1091/mbc.E02-06-0338

Dynamic processing of neuropeptides - Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport 10.1385/jmn:18:3:223

Yeast Vps55p, a functional homolog of human obesity receptor gene-related protein, is involved in late endosome to vacuole trafficking 10.1091/mbc.01-12-0597

Targeting of lysosomal proteins 10.1006/scdb.2000.0168

Unique evolution of neurohypophysial hormones in cartilaginous fishes: Possible implications for urea-based osmoregulation 10.1002/(sici)1097-010x(19991001)284:5<475::aid-jez2>3.0.co;2-9

Adaptive evolution of water homeostasis regulation in amphibians: Vasotocin and hydrins 10.1016/s0248-4900(97)83380-1

Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2 10.1073/pnas.94.13.6646

Molecular evolution of neurohypophysial hormones in relation to osmoregulation: the two fish options 10.1023/a:1007720909113

Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication 10.1111/cmi.12804

Entry and release of hepatitis C virus in polarized human hepatocytes. 10.1128/jvi.00478-17

An ecological approach to discover new bioactive extracts and products: the case of extremophile plants. 10.1111/jphp.12728

Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling. 10.1016/j.molmet.2016.10.009

Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. 10.1128/jvi.00048-17

Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics. 10.1016/j.jviromet.2017.04.009

Hepatitis C virus life cycle and lipid metabolism. 10.3390/biology3040892

Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity 10.1172/jci.insight.98081

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses 10.1099/jgv.0.001099

Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein 10.1128/JVI.01459-18

QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence 10.3390/v11020165

Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants 10.3390/pathogens10020172

Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses 10.1101/2021.05.19.444823

The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. 10.1074/jbc.ra119.008964

Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. 10.1007/s00018-020-03745-y

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. 10.1128/jvi.02009-18

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress 10.3390/cells10082047

Karin Seron

Seron Karin

ORCID: 0000-0002-9667-133X

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans 10.1128/jvi.03647-14

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors 10.1128/jvi.01402-14

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors 10.1016/j.bmcl.2014.07.051

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? 10.3390/v4102197

Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway 10.1074/jbc.M111.224857

Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein 10.1099/vir.0.015339-0

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity 10.1073/pnas.0706671104

ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity 10.2337/diabetes.55.02.06.db05-0971

Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women 10.1016/j.bbrc.2006.07.068

Genetic study of the CD36 gene In a French diabetic population 10.1016/s1262-3636(07)70143-x

GAD2 on chromosome 10p12 is a candidate gene for human obesity 10.1371/journal.pbio.0000068

Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii 10.1046/j.1432-1327.2000.01749.x

Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants 10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q

Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase 10.1016/s0166-0934(96)02166-0

Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997) 10.1016/s0166-0934(96)02249-5

Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells 10.1006/viro.1996.0246

Gene expression from viral RNA genomes 10.1007/bf00039391

Vascular movement of plant viruses 10.1094/mpmi-9-0435

IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS 10.1016/s0923-2516(06)80049-x

Entry and release of hepatitis C virus in polarized human hepatocytes. 10.1128/jvi.00478-17

An ecological approach to discover new bioactive extracts and products: the case of extremophile plants. 10.1111/jphp.12728

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. 10.1128/jvi.00404-16

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. 10.1016/j.antiviral.2016.07.011

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus 10.1101/325126

Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource. 10.1016/j.jep.2020.112735

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus. 10.1021/acsami.9b15032

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. 10.1128/jvi.02009-18

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes". 10.1128/jvi.00309-18

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

A yeast t-SNARE involved in endocytosis. 10.1091/mbc.9.10.2873

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Priscille Brodin

Brodin Priscille

ORCID: 0000-0003-0991-7344

Email: priscille.brodin@inserm.fr

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364

Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535

Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009

Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016

High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114

Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b

Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648

Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779

Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u

The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573

Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675

Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a

High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044

Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583

High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645

Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062

Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064

Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006

Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006

High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06

Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0

Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049

Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0

CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322

Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b

Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681

Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2

Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831

Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029

A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025

Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086

Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129

A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627

Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360

Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902

Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13

Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18

A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J

Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516

Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127

Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277

Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Worms' Antimicrobial Peptides. 10.3390/md17090512

T(oo)bAd. 10.1038/s41589-019-0347-x

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Cell microbiology interview 10.1111/cmi.13288

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

Philip Meuleman

Meuleman Philip

ORCID: 0000-0001-6821-234X

Blocking HCV entry as potential antiviral therapy 10.2217/fvl.12.47

HCV animal models and liver disease 10.1016/j.jhep.2014.07.013

Human but Not Mouse Hepatocytes Respond to Interferon-Lambda In Vivo 10.1371/journal.pone.0087906

Hepatitis C virus infection and related liver disease: the quest for the best animal model 10.3389/fmicb.2013.00212

The emergence of hepatitis E virus in Europe 10.2217/fvl.15.29

Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice 10.1002/(sici)1521-4141(199810)28:10<3221::aid-immu3221>3.0.co;2-s

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection 10.1172/jci70349

Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice 10.1186/1475-2875-12-430

Human Skin-Derived Precursor Cells Are Poorly Immunogenic and Modulate the Allogeneic Immune Response 10.1002/stem.1692

Metabolism of methylstenbolone studied with human liver microsomes and the uPA +/+ -SCID chimeric mouse model 10.1002/bmc.3105

Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1 10.1074/jbc.m114.617787

Is hepatitis E virus an emerging problem in industrialized countries? 10.1002/hep.27990

Animal models for the study of HCV 10.1016/j.coviro.2015.04.009

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody 10.1038/nbt.3179

Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1 10.1002/hep.28111

Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model 10.1093/jac/dkv019

G09 : Targeting a host-cell entry factor barricades antiviral resistant HCV variants from on-therapy breakthrough in human-liver mice 10.1016/s0168-8278(15)30058-1

P0674 : Clinically approved T-type calcium channel inhibitors prevent hepatitis C virus (HCV) membrane fusion in a genotype-dependent manner 10.1016/s0168-8278(15)30878-3

P0676 : Clearance of persistent hepatitis c virus infection using a monoclonal antibody specific for tight junction protein claudin-1 10.1016/s0168-8278(15)30880-1

In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200 10.1002/rcm.6673

In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) 10.1007/s11419-013-0179-4

Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum 10.1186/1475-2875-13-136

Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication 10.1371/journal.pone.0081783

A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites 10.7554/elife.03582

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents 10.1002/hep.27196

Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant 10.1128/jvi.01362-07

Immune Suppression Uncovers Endogenous Cytopathic Effects of the Hepatitis B Virus 10.1128/jvi.80.6.2797-2807.2006

O.055 The human liver-uPA-SCID mouse: a chimeric rodent model for the study of viral hepatitis 10.1016/s1386-6532(06)80061-2

A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice 10.1016/s0006-291x(03)01388-3

Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity 10.1128/jvi.02356-06

PREVENTION OF HEPATITIS B INFECTIONS : VACCINATION AND ITS LIMITATIONS 10.1179/acb.2001.032

101 HUMAN MONOCLONAL ANTIBODIES TARGETING SR-BI PREVENT HCV ENTRY AND VIRAL SPREAD IN VIVO 10.1016/s0168-8278(11)60103-7

827 EXPERIMENTAL HCV VACCINE COMBINING ADENOVIRUS AND PROTEIN ELICITS POTENT T-CELL RESPONSES AND NEUTRALIZING ANTIBODIES IN RODENTS 10.1016/s0168-8278(12)60839-3

861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO 10.1016/s0168-8278(12)60873-3

Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization 10.1128/jvi.01594-10

Griffithsin Has Antiviral Activity against Hepatitis C Virus 10.1128/aac.00633-11

In Vivo Inhibition of Anti-Hepatitis B Virus Core Antigen (HBcAg) Immunoglobulin G Production by HBcAg-Specific CD4+ Th1-Type T-Cell Clones in a hu-PBL-NOD/SCID Mouse Model 10.1128/jvi.75.23.11449-11456.2001

O.053 The human liver uPA-SCID mouse, a preclinical model to test anti-hepatitis C compounds 10.1016/s1386-6532(06)80060-0

Role of the Hepatitis C Virus Core+1 Open Reading Frame and Core cis-Acting RNA Elements in Viral RNA Translation and Replication 10.1128/jvi.01640-08

Development and Application of Hepatitis C Reporter Viruses with Genotype 1 to 7 Core-Nonstructural Protein 2 (NS2) Expressing Fluorescent Proteins or Luciferase in Modified JFH1 NS5A 10.1128/jvi.00049-11

Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses 10.1128/jvi.03574-13

Animal Models to Study Hepatitis C Virus Infection. 10.3389/fimmu.2018.01032

Absence of zoonotic hepatitis E virus infection in Flemish dairy cows. 10.1016/j.ijfoodmicro.2018.05.009

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. 10.1038/s41598-018-24762-9

Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. 10.1002/hep4.1152

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. 10.1016/j.virol.2017.10.019

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. 10.1016/j.antiviral.2017.10.015

Murine Tissues of Human Liver Chimeric Mice Are Not Susceptible to Hepatitis E Virus Genotypes 1 and 3. 10.1093/infdis/jix422

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. 10.1053/j.gastro.2017.09.020

Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. 10.1016/j.antiviral.2017.02.011

Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. 10.1016/j.antiviral.2017.01.001

Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG® KO Mice. 10.1007/978-1-4939-6506-9_8

Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. 10.1038/nmicrobiol.2016.247

Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. 10.1128/mbio.01915-16

Hepatitis E virus in acute liver failure: An unusual suspect? 10.1002/hep.28759

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. 10.1128/jvi.00404-16

Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. 10.3390/v8060176

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. 10.1099/jgv.0.000493

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. 10.1136/gutjnl-2015-311109

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. 10.1002/hep.28428

In vitro and in vivo metabolism studies of dimethazine. 10.1002/bmc.3668

Metabolic studies of prostanozol with the uPA-SCID chimeric mouse model and human liver microsomes. 10.1016/j.steroids.2016.01.005

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. 10.1136/gutjnl-2015-310300

Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. 10.1053/j.gastro.2015.09.014

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. 10.1136/gutjnl-2014-309045

Host cell mTORC1 is required for HCV RNA replication. 10.1136/gutjnl-2014-308971

Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice. 10.1007/978-1-4939-2815-6_5

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. 10.3748/wjg.v20.i43.15975

Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. 10.1136/gutjnl-2012-304299

Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice 10.1016/j.jhep.2012.02.018

The Green Tea Polyphenol, Epigallocatechin-3-Gallate, Inhibits Hepatitis C Virus Entry 10.1002/hep.24610

In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus 10.1002/hep.24171

Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice 10.1016/j.jhep.2010.03.024

Steroid metabolism in chimeric mice with humanized liver 10.1002/dta.67

The uPA(+/+)-SCID Mouse with Humanized Liver as a Model for in Vivo Metabolism of 4-Androstene-3,17-dione 10.1124/dmd.109.028183

Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo 10.1002/hep.22547

Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain 10.1002/hep.22244

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro 10.1073/pnas.0511218103

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera 10.1002/hep.20657

Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. 10.1016/j.antiviral.2017.09.006

The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. 10.1016/j.antiviral.2018.07.010

Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. 10.1093/infdis/jiy386

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. 10.1128/jvi.00939-18

Erratum: Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. 10.1038/nmicrobiol.2017.12

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. 10.1016/j.jhep.2019.01.033

Animal Models for Hepatitis E virus. 10.3390/v11060564

Hepatitis E virus prevalence in Flemish blood donors. 10.1111/jvh.13161

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. 10.1093/infdis/jiz171

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle. 10.1038/s41598-019-42737-2

Infectivity and stability of hepatitis C virus in different perfusion solutions. 10.1111/tid.13135

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections. 10.1093/infdis/jiaa036

Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. 10.1073/pnas.1919035117

Robust hepatitis E virus infection and transcriptional response in human hepatocytes. 10.1073/pnas.1912307117

Updates in Hepatitis E virus (HEV) field; lessons learned from human liver chimeric mice. 10.1002/rmv.2086

Thermostability of seven hepatitis C virus genotypes in vitro and in vivo 10.1111/jvh.12055

A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo 10.1002/hep.24692

STAT transcriptional activity is controlled by regulated deacetylation 10.1016/j.cyto.2012.06.223

The Sin3a repressor complex is a master regulator of STAT transcriptional activity 10.1073/pnas.1206458109

Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase 10.1021/jm1013105

Lipoprotein Lipase Inhibits Hepatitis C Virus (HCV) Infection by Blocking Virus Cell Entry 10.1371/journal.pone.0026637

Metabolic studies with promagnon, methylclostebol and methasterone in the uPA(+/+)-SCID chimeric mice 10.1016/j.jsbmb.2011.06.010

Challenge Pools of Hepatitis C Virus Genotypes 1-6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liver-Chimeric Mouse Models 10.1086/651579

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation 10.1084/jem.20090766

Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism 10.1002/dta.56

Detection and Characterization of a New Metabolite of 17 alpha-Methyltestosterone 10.1124/dmd.109.028373

Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry 10.1016/j.steroids.2009.05.004

HCV Animal Models: A Journey of More than 30 Years 10.3390/v1020222

Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations 10.1371/journal.ppat.1000475

uPA(+/+)-SCID Mouse with Humanized Liver as a Model for In Vivo Metabolism of Exogenous Steroids: Methandienone as a Case Study 10.1373/clinchem.2008.119396

Development and validation of a quantitative gas chromatography-mass spectrometry method for the detection of endogenous androgens in mouse urine 10.1016/j.chroma.2007.11.077

The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV 10.1016/j.antiviral.2008.07.006

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse 10.1053/j.gastro.2007.07.007

Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection 10.1016/j.cca.2005.09.022

The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level 10.1016/j.jim.2004.01.001

Nathalie deboosere

deboosere Nathalie

ORCID: 0000-0002-2873-5485

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227

Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007

Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013

Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011

Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002

Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10

A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018

Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013

Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007

Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015

Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3

Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030

Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5

[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650

[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14

Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040

Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u

A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648

Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675

High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645

Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583

Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07

[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062

Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05

Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006

Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004

CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Jean Dubuisson

Dubuisson Jean

ORCID: 0000-0003-1626-7693

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses 10.1016/j.jhep.2015.12.021

Hepatitis C Virus Resistance to Carbohydrate-Binding Agents 10.1371/journal.pone.0149064

Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus 10.1128/JVI.00404-16

Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication 10.1111/cmi.12572

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin 10.1016/j.antiviral.2016.07.011

Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope 10.1371/journal.ppat.1005476

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver 10.1136/gutjnl-2015-311109

Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats 10.3390/v7122937

Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry 10.1039/c4nr03875d

Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans 10.1128/JVI.03647-14

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro 10.1371/journal.pone.0142539

HCV envelope glycoproteins in virion assembly and entry 10.2217/FVL.14.114

Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion 10.1128/JVI.00991-15

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A 10.1128/JVI.00192-15

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/JVI.01473-15

Regulation of core expression during the hepatitis C virus life cycle 10.1099/vir.0.070433-0

A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice 10.1002/bab.1223

Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution 10.1128/JVI.01745-13

HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin 10.3748/wjg.v20.i1.148

Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis 10.5812/hepatmon.17812

Hepatitis C virus life cycle and lipid metabolism 10.3390/biology3040892

Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein 10.1371/journal.pone.0111333

Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors 10.1128/JVI.01402-14

Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion 10.3390/v6031149

Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation 10.1016/j.vaccine.2014.01.046

Virology and cell biology of the hepatitis C virus life cycle - An update 10.1016/j.jhep.2014.06.031

Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization 10.1093/infdis/jit376

Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein 10.1128/JVI.02659-12

EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry 10.1111/cmi.12112

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells 10.1371/journal.pone.0074491

Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus 10.1371/journal.pone.0070809

Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics 10.1021/am403770q

Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies 10.2217/fvl.13.75

The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus 10.1002/hep.26273

Virus-neutralizing antibodies to hepatitis C virus 10.1111/jvh.12094

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry 10.1002/hep.24803

Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? 10.3390/v4102197

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets 10.1136/gutjnl-2012-302048

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle 10.1002/hep.25501

Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion 10.1074/jbc.M112.382341

Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein 10.1099/vir.0.028092-0

Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships 10.1099/vir.0.034314-0

Griffithsin Has Antiviral Activity against Hepatitis C Virus 10.1128/AAC.00633-11

HCV replication and assembly: a play in one act 10.2217/FVL.11.69

Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype 10.1128/JVI.01332-10

Hepatitis C Virus Assembly Imaging 10.3390/v3112238

Hepatitis C virus entry into the hepatocyte 10.2478/s11535-011-0076-y

Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies 10.1016/j.yexcr.2011.08.018

Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2 10.1128/JVI.02170-10

Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection 10.1074/jbc.M111.220103

NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly 10.1371/journal.ppat.1001278

The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response 10.3390/v3101909

Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus 10.1128/JVI.01180-10

Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein 10.1099/vir.0.015339-0

Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity 10.1128/JVI.01393-10

Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication 10.1128/JVI.01190-09

Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets 10.3390/v2081782

NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus 10.1074/jbc.M110.122895

Recent Advances in Hepatitis C Virus Cell Entry 10.3390/v2030692

Role of lipid metabolism in hepatitis C virus assembly and entry 10.1042/BC20090125

Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions 10.1128/JVI.01548-10

Enhanced anti-HCV activity of interferon alpha 17 subtype 10.1186/1743-422X-6-70

Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial 10.1111/j.1365-2893.2008.01058.x

N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins 10.1684/vir.2009.0270

Occludin, the final essential factor for HCV entry? 10.2217/FVL.09.13

Rapid synchronization of hepatitis C virus infection by magnetic adsorption 10.1016/j.jviromet.2008.11.015

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry 10.1186/1471-2180-9-111

Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry 10.1111/j.1462-5822.2007.01070.x

Early steps of the hepatitis C virus life cycle 10.1111/j.1462-5822.2007.01107.x

Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein 10.1128/JVI.02582-07

Hepatitis C virus entry into host cells 10.1007/s00018-007-7291-8

Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus 10.1086/589777

Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent 10.1128/JVI.01443-07

The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry 10.1371/journal.pone.0001866

CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection 10.1128/JVI.01573-06

Hepatitis C virus proteins 10.3748/wjg.v13.i17.2406

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus 10.1073/pnas.0705522104

New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu 10.1186/1742-4690-4-8

Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors 10.1099/vir.0.82465-0

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins 10.1099/vir.0.82872-0

The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes 10.1007/s00232-007-9003-6

The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein 10.1128/JVI.00127-07

Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry 10.1128/JVI.02198-06

Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles 10.1099/vir.0.81503-0

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans 10.1074/jbc.M602431200

Hepatitis C virus entry depends on clathrin-mediated endocytosis 10.1128/JVI.00024-06

Hepatitis C virus entry: potential receptors and their biological functions 10.1099/vir.0.81646-0

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI 10.1074/jbc.M602706200

High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry 10.1099/vir.0.81932-0

Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system 10.1002/hep.21406

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus 10.1128/JVI.80.6.2832-2841.2006

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2 10.1128/JVI.79.21.13199-13208.2005

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets 10.1099/vir.0.81169-0

Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry 10.1128/JVI.79.24.15331-15341.2005

Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis 10.1128/JVI.79.16.10826-10829.2005

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus 10.1002/hep.20542

Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer 10.1099/vir.0.81140-0

High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I 10.1074/jbc.M411600200

Interactions between virus proteins and host cell membranes during the viral life cycle 10.1016/S0074-7696(05)45006-8

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins 10.1128/JVI.79.13.8400-8409.2005

Characterization of functional hepatitis C virus envelope glycoproteins 10.1128/JVI.78.6.2994-3002.2004

Functional hepatitis C virus envelope glycoproteins 10.1016/j.biolcel.2004.03.008

Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions 10.1128/JVI.78.17.9224-9232.2004

Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein 10.4049/jimmunol.173.1.446

Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication 10.1007/s00705-003-0291-6

Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions 10.1074/jbc.M406315200

Structural biology of hepatitis C virus 10.1002/hep.20032

The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals 10.1128/JVI.78.22.12591-12602.2004

Another putative receptor for hepatitis C virus 10.1002/hep.510370327

CD81-dependent binding of hepatitis C virus E1E2 heterodimers 10.1128/JVI.77.19.10677-10683.2003

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor 10.1074/jbc.M305289200

Characterization of the expression of the hepatitis C virus F protein 10.1099/vir.0.19065-0

Glycosylation of hepatitis C virus envelope proteins 10.1016/S0300-9084(03)00004-X

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes 10.1084/jem.20021756

Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope 10.1128/JVI.77.2.813-820.2003

Topology of hepatitis C virus envelope glycoproteins 10.1002/rmv.391

Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines 10.1128/JVI.76.3.1181-1193.2002

Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line 10.1093/glycob/12.2.95

Interaction of hepatitis C virus proteins with host cell membranes and lipids 10.1016/S0962-8924(02)02383-8

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines 10.1006/viro.2001.1212

Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment 10.1074/jbc.M111020200

Subcellular localization and topology of the p7 polypeptide of hepatitis C virus 10.1128/JVI.76.8.3720-3730.2002

Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins 10.1093/emboj/cdf295

Biogenesis of hepatitis C virus envelope glycoproteins 10.1099/0022-1317-82-11-2589

Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2 10.1099/0022-1317-82-7-1629

Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization 10.1053/jhep.2001.22175

Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients 10.1128/JVI.75.17.8240-8250.2001

Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins 10.1128/JVI.74.8.3623-3633.2000

Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding 10.1099/0022-1317-81-12-2873

Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein 10.1128/JVI.74.2.702-709.2000

Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein 10.1074/jbc.M004326200

Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells 10.1046/j.1432-1327.2000.01111.x

The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization 10.1074/jbc.M003003200

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex 10.1099/0022-1317-80-4-887

Characterization of aggregates of hepatitis C virus glycoproteins 10.1099/0022-1317-80-12-3099

Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum 10.1023/A:1020228725997

Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties 10.1006/viro.1998.9202

Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval 10.1074/jbc.273.48.32088

Characterization of truncated forms of hepatitis C virus glycoproteins 10.1099/0022-1317-78-9-2299

SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H 10.1016/S0042-6822(95)80083-2

ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE 10.1006/viro.1993.1471

IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES 10.1007/BF01309747

EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE 10.1016/0166-0934(92)90010-B

IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4 10.1099/0022-1317-73-5-1293

MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV 10.1099/0022-1317-73-8-2031

MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4 10.1016/0378-1135(92)90037-T

PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT 10.1099/0022-1317-73-1-189

A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE 10.1016/0166-0934(91)90133-K

ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4 10.1099/0022-1317-72-3-715

BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS 10.1016/0378-1135(91)90132-Y

CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM 10.1099/0022-1317-72-5-1195

COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4 10.1099/0022-1317-72-5-1145

FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63 10.1136/vr.128.26.614

GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES 10.1007/BF01319227

TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS 10.1099/0022-1317-72-6-1429

Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis 10.1099/0022-1317-71-1-133

Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization 10.1099/0022-1317-71-3-647

EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE 10.1016/0378-1135(89)90022-9

PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4 10.1016/0378-1135(89)90096-5

PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES 10.1099/0022-1317-70-7-1743

BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS 10.1016/0378-1135(88)90015-6

Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly 10.1128/JVI.00048-17

Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination 10.1111/pbi.12743

Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly 10.1016/j.biochi.2017.06.009

Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics 10.1016/j.jviromet.2017.04.009

Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes 10.1128/JVI.00478-17

Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus 10.1111/jvh.12767

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1 10.1016/j.virol.2017.10.019

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein 10.1053/j.gastro.2017.09.020

Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication 10.1111/cmi.12804

Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes 10.1053/j.gastro.2018.03.020

Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial) 10.1007/s40271-017-0232-1

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study 10.1371/journal.pone.0145105

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients 10.1111/jvh.12433

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain 10.1128/JVI.00939-18

HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region 10.1099/jgv.0.001074

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses 10.1099/jgv.0.001099

Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies 10.3389/fimmu.2018.00910

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication 10.1101/469361

Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein 10.1128/JVI.01459-18

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/JVI.02009-18

Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir 10.1016/j.antiviral.2019.05.002

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle 10.1038/s41598-019-42737-2

Le virus de l’hépatite E 10.1051/medsci/2018299

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture 10.1371/journal.pone.0198226

Function of the HCV E1 envelope glycoprotein in viral entry and assembly 10.2217/fvl-2018-0180

Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV 10.1007/978-1-4939-8976-8_2

Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit 10.1016/j.jcv.2019.104206

A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice 10.1186/s12879-019-4571-5

Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver 10.3390/cells8101296

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus 10.1021/acsami.9b15032

The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal 10.1074/jbc.ra119.008964

Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection 10.1111/tra.12680

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model 10.1101/2020.04.22.056754

Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers 10.1101/2020.05.12.20098236

Les coronavirus, ennemis incertains 10.1051/medsci/2020113

Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource 10.1016/j.jep.2020.112735

Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants 10.3390/pathogens10020172

Fluoxetine Can Inhibit SARS-CoV-2 In Vitro 10.3390/microorganisms9020339

Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds 10.3390/pathogens10070861

Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress 10.3390/cells10082047

Ahmed Atef Mesalam

Mesalam Ahmed Atef / Ahmed Atef Mesalam

ORCID: 0000-0003-4605-2976

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization 10.3748/wjg.v20.i43.15975

Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate 10.1007/s00705-009-0500-z

Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus 10.1128/JVI.00404-16

Animal models to study hepatitis C virus infection 10.3389/fimmu.2018.01032

Polyphenols inhibit hepatitis C virus entry by a new mechanism of action 10.1128/JVI.01473-15

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line 10.1099/jgv.0.000493

Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate 10.1002/jmv.24977

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice 10.1136/gutjnl-2014-309045

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1 10.1016/j.virol.2017.10.019

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo 10.1016/j.antiviral.2017.10.015

Mouse systems to model hepatitis C virus treatment and associated resistance 10.3390/v8060176

Functional study of the C-Terminal part of the hepatitis C Virus E1 ectodomain 10.1128/JVI.00939-18

Induction of Oxidative Stress and Mitochondrial Dysfunction by Juglone Affects the Development of Bovine Oocytes 10.3390/ijms22010168

Hepatitis C Virus Vaccine Development: A Step Forward 10.1093/infdis/jiaa644

Nicotinamide Supplementation during the In Vitro Maturation of Oocytes Improves the Developmental Competence of Preimplantation Embryos: Potential Link to SIRT1/AKT Signaling 10.3390/cells9061550

Melatonin Abrogates the Anti-Developmental Effect of the AKT Inhibitor SH6 in Bovine Oocytes and Embryos 10.3390/ijms20122956

Melatonin Alleviates the Toxicity of High Nicotinamide Concentrations in Oocytes: Potential Interaction with Nicotinamide Methylation Signaling 10.1155/2021/5573357